SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Y.-P. Lim, C.-L. Lin, D.-Z. Hung, Y.-N. Lin, C.-H. Kao, Anti-tuberculosis treatments and risk of hepatocellular carcinoma in tuberculosis patients with liver cirrhosis: a population-based case–control study, European Journal of Clinical Microbiology & Infectious Diseases, 2014,

    CrossRef

  2. 2
    Margaret S. Coleman, Karen J. Marienau, Nina Marano, Suzanne M. Marks, Martin S. Cetron, Economics of United States tuberculosis airline contact investigation policies: A return on investment analysis, Travel Medicine and Infectious Disease, 2014, 12, 1, 63

    CrossRef

  3. 3
    Carmen R. Gallardo, María Teresa Gea Velázquez de Castro, Juana Requena Puche, Juan José Miralles Bueno, María Vicenta Rigo Medrano, Jesús M. Aranaz Andrés, Factores asociados a la adherencia en el tratamiento de la infección tuberculosa, Atención Primaria, 2014, 46, 1, 6

    CrossRef

  4. 4
    Surendra K Sharma, Anju Sharma, Tamilarasu Kadhiravan, Prathap Tharyan, Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB, Evidence-Based Child Health: A Cochrane Review Journal, 2014, 9, 1
  5. 5
    A. Souto, J. R. Maneiro, E. Salgado, L. Carmona, J. J. Gomez-Reino, Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies, Rheumatology, 2014, 53, 10, 1872

    CrossRef

  6. 6
    Martin Krátký, Jarmila Vinšová, Eva Novotná, Jiřina Stolaříková, Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase, European Journal of Pharmaceutical Sciences, 2014, 53, 1

    CrossRef

  7. 7
    Andrew L. Bozarth, Alan R. Salkind, Tuberculosis, Hospital Medicine Clinics, 2014, 3, 1, e50

    CrossRef

  8. 8
    Gregory J Fox, Guy B Marks, Warwick J Britton, Clinical Insights: Tuberculosis Prevention, 2014,

    CrossRef

  9. 9
    Elizabeth C. Hsia, John J. Cush, Eric L. Matteson, Anna Beutler, Mittie K. Doyle, Benjamin Hsu, Stephen Xu, Mahboob U. Rahman, Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti–tumor necrosis factor antibody, in Phase III clinical trials, Arthritis Care & Research, 2013, 65, 2
  10. You have free access to this content10
    CYNTHIA BIN-ENG CHEE, MARTINA SESTER, WENHONG ZHANG, CHRISTOPH LANGE, Diagnosis and treatment of latent infection with Mycobacterium tuberculosis, Respirology, 2013, 18, 2
  11. 11
    Jimena Sanz-Bueno, María Castellanos-González, Mario Fernández-Ruiz, Manuel Lizasoain, Raquel Rivera, Pautas alternativas en el tratamiento de la infección tuberculosa latente en el paciente con psoriasis, Piel, 2013, 28, 8, 448

    CrossRef

  12. 12
    Glen S. Hazlewood, David Naimark, Michael Gardam, Vivian Bykerk, Claire Bombardier, Prophylaxis for Latent Tuberculosis Infection Prior to Anti–Tumor Necrosis Factor Therapy in Low-Risk Elderly Patients With Rheumatoid Arthritis: A Decision Analysis, Arthritis Care & Research, 2013, 65, 11
  13. 13
    R. N. Coler, S. Bertholet, S. O. Pine, M. T. Orr, V. Reese, H. P. Windish, C. Davis, M. Kahn, S. L. Baldwin, S. G. Reed, Therapeutic Immunization against Mycobacterium tuberculosis Is an Effective Adjunct to Antibiotic Treatment, Journal of Infectious Diseases, 2013, 207, 8, 1242

    CrossRef

  14. 14
    Shou-Chien Chen, Kwo-Liang Chen, Kou-Huang Chen, Shun-Tien Chien, Kow-Tong Chen, Updated diagnosis and treatment of childhood tuberculosis, World Journal of Pediatrics, 2013, 9, 1, 9

    CrossRef

  15. 15
    S. H. LEE, J.-J. YIM, H. J. KIM, T. S. SHIM, H. S. SEO, Y. S. CHO, H.-K. LEE, Y. M. LEE, E. J. LEE, W. J. LEW, Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak, Epidemiology and Infection, 2012, 140, 06, 1028

    CrossRef

  16. 16
    Toshiko Miyata, Chan-Ick Cheigh, Nicola Casali, Amador Goodridge, Olivera Marjanovic, Lon V. Kendall, Lee W. Riley, An adjunctive therapeutic vaccine against reactivation and post-treatment relapse tuberculosis, Vaccine, 2012, 30, 2, 459

    CrossRef

  17. 17
    Tyler E. Weant, Abigail Norris Turner, Maureen Murphy-Weiss, David M. Murray, Shu-Hua Wang, Can Social History Variables Predict Prison Inmates’ Risk for Latent Tuberculosis Infection?, Tuberculosis Research and Treatment, 2012, 2012, 1

    CrossRef

  18. 18
    Emilio Fábrega, Blanca Sampedro, Joaquín Cabezas, Fernando Casafont, Miguel Ángel Mieses, Irene Moraleja, Javier Crespo, Fernando Pons-Romero, Chemoprophylaxis with isoniazid in liver transplant recipients, Liver Transplantation, 2012, 18, 9
  19. 19
    Seok Jin Kang, Yeo Hyang Kim, Chi Young Jung, Hee Jung Lee, Myung Chul Hyun, Clinical Characteristics and Radiologic Patterns of Adelescents with Pulmonary Tuberculosis: Relevance to the Reactive Tuberculosis, Pediatric Allergy and Respiratory Disease, 2012, 22, 2, 163

    CrossRef

  20. 20
    I. Abubakar, H. R. Stagg, T. Cohen, P. Mangtani, L. C. Rodrigues, L. Pimpin, J. M. Watson, S. B. Squire, A. Zumla, Controversies and Unresolved Issues in Tuberculosis Prevention and Control: A Low-Burden-Country Perspective, Journal of Infectious Diseases, 2012, 205, suppl 2, S293

    CrossRef

  21. 21
    A. Zumla, I. Abubakar, M. Raviglione, M. Hoelscher, L. Ditiu, T. D. Mchugh, S. B. Squire, H. Cox, N. Ford, R. McNerney, B. Marais, M. Grobusch, S. D. Lawn, G.-B. Migliori, P. Mwaba, J. O'Grady, M. Pletschette, A. Ramsay, J. Chakaya, M. Schito, S. Swaminathan, Z. Memish, M. Maeurer, R. Atun, Drug-Resistant Tuberculosis--Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs, Journal of Infectious Diseases, 2012, 205, suppl 2, S228

    CrossRef

  22. 22
    Jihyun Lee, Soojung Gong, Byounghoon Lee, Soyoung Lee, Jungae Lee, Naeyu Kim, Miliary tuberculosis occurred after immunosuppressive drug in PNH patient with completely cured tuberculosis; a case report, Annals of Clinical Microbiology and Antimicrobials, 2012, 11, 1, 12

    CrossRef

  23. 23
    Kevin P. Cain, Katie N. Garman, Kayla F. Laserson, Odile P. Ferrousier-Davis, Abraham G. Miranda, Charles D. Wells, Connie A. Haley, Moving toward Tuberculosis Elimination, American Journal of Respiratory and Critical Care Medicine, 2012, 186, 3, 273

    CrossRef

  24. 24
    Neela D Goswami, Lara Gadkowski, Carla Piedrahita, Deborah Bissette, Marshall Ahearn, Michela LM Blain, Truls Østbye, Jussi Saukkonen, Jason E Stout, Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study, BMC Public Health, 2012, 12, 1, 468

    CrossRef

  25. 25
    Mehmet Ugur Cevik, Abdullah Acar, Halis Tanriverdi, Sefer Varol, Adalet Arikanoglu, Yavuz Yucel, Esref Akil, Muharrem Yunce, Aysun Ekinci, Toxic Effects of Isoniazid and Rifampicin on Rat Brain Tissue: The Preventive Role of Caffeic Acid Phenethyl Ester, International Journal of Pharmacology, 2012, 8, 6, 555

    CrossRef

  26. 26
    P. Fraisse, Traitement des infections tuberculeuses latentes, Revue des Maladies Respiratoires, 2012, 29, 4, 579

    CrossRef

  27. 27
    Dione Benjumea, Tratamiento para la infección latente por tuberculosis en niños: recomendaciones internacionales y para Colombia, Infectio, 2012, 16, 3, 173

    CrossRef

  28. 28
    José M. Peña, Aclaraciones al documento de consenso sobre diagnóstico, tratamiento y prevención de la tuberculosis, Enfermedades Infecciosas y Microbiología Clínica, 2011, 29, 2, 162

    CrossRef

  29. 29
    Lucila Marquez, Jeffrey R Starke, Diagnosis and management of TB in children: an update, Expert Review of Anti-infective Therapy, 2011, 9, 12, 1157

    CrossRef

  30. 30
    Margarita O. Shleeva, Yulia K. Kudykina, Galina N. Vostroknutova, Natalia E. Suzina, Andrey L. Mulyukin, Arseny S. Kaprelyants, Dormant ovoid cells of Mycobacterium tuberculosis are formed in response to gradual external acidification, Tuberculosis, 2011, 91, 2, 146

    CrossRef

  31. 31
    Wing Wai Yew, Michael Cynamon, Ying Zhang, Emerging drugs for the treatment of tuberculosis, Expert Opinion on Emerging Drugs, 2011, 16, 1, 1

    CrossRef

  32. 32
    Hannah P. Gideon, JoAnne L. Flynn, Latent tuberculosis: what the host “sees”?, Immunologic Research, 2011, 50, 2-3, 202

    CrossRef

  33. 33
    Satoshi Kubo, Kunihiro Yamaoka, Kazuyoshi Saito, Yoshiya Tanaka, Péricardite induite par l’administration prophylactique d’isoniazide chez un patient atteint de polyarthrite rhumatoïde, Revue du Rhumatisme, 2011, 78, 2, 191

    CrossRef

  34. 34
    Satoshi Kubo, Kunihiro Yamaoka, Kazuyoshi Saito, Yoshiya Tanaka, Pericarditis induced by prophylactic administration of isoniazid in a patient with rheumatoid arthritis, Joint Bone Spine, 2011, 78, 1, 99

    CrossRef

  35. You have free access to this content35
    Euzebiusz JAMROZIK, Arthur William MUSK, Respiratory health issues in the Asia–Pacific region: An overview, Respirology, 2011, 16, 1
  36. 36
    Alimuddin Zumla, Rifat Atun, Markus Maeurer, Peter Mwaba, Zhenkun Ma, Justin O’Grady, Matthew Bates, Keertan Dheda, Michael Hoelscher, John Grange, Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection, Point de vue: Dogmes scientifiques, paradoxes et mystères de l’infection latente àMycobacterium tuberculosis, Punto de vista: Dogmas científicos, paradojas y misterios de la infección latente de Mycobacterium tuberculosis, Tropical Medicine & International Health, 2011, 16, 1
  37. 37
    CHI CHIU LEUNG, DAVID FELLER-KOPMAN, MICHAEL S. NIEDERMAN, STEPHEN G. SPIRO, Year in review 2010: Tuberculosis, pleural diseases, respiratory infections, Respirology, 2011, 16, 3
  38. 38
    Paul M. Kelly, Commentary on ‘Reminder Systems and Late Patient Tracers in the Diagnosis and Management of Tuberculosis’, Evidence-Based Child Health: A Cochrane Review Journal, 2010, 5, 3
  39. You have free access to this content39
    Eric L. NUERMBERGER, Melvin K. SPIGELMAN, Wing Wai YEW, Current development and future prospects in chemotherapy of tuberculosis, Respirology, 2010, 15, 5
  40. 40
    Surendra K Sharma, Anju Sharma, Tamilarasu Kadhiravan, Prathap Tharyan, Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB, The Cochrane Library,